Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors

BACKGROUND: Management of gastrointestinal stromal tumors (GISTs) has been transformed with tyrosine kinase inhibitors (TKIs). While data on optimal duration of adjuvant imatinib remains elusive, guidelines for administration of neoadjuvant TKIs remain unknown. METHODS: Under an institutional review...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Surg Oncol
Autors principals: Bednarski, Brian K., Araujo, Dejka M., Yi, Min, Torres, Keila E., Lazar, Alexander, Trent, Jonathan C., Cormier, Janice N., Pisters, Peter W. T., Lev, Dina Chelouche, Pollock, Raphael E., Feig, Barry W., Hunt, Kelly K.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524653/
https://ncbi.nlm.nih.gov/pubmed/24639192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-014-3632-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars